These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

208 related items for PubMed ID: 31429028

  • 1. Inhibition of Aurora A Kinase in Combination with Chemotherapy Induces Synthetic Lethality and Overcomes Chemoresistance in Myc-Overexpressing Lymphoma.
    Park SI, Lin CP, Ren N, Angus SP, Dittmer DP, Foote M, Parton T, Bhatt AP, Fedoriw YD, Roth DP, Cann ML, Johnson GL, Damania B.
    Target Oncol; 2019 Oct; 14(5):563-575. PubMed ID: 31429028
    [Abstract] [Full Text] [Related]

  • 2. c-Myc Is a Major Determinant for Antitumor Activity of Aurora A Kinase Inhibitor MLN8237 in Thyroid Cancer.
    Li Y, Li X, Pu J, Yang Q, Guan H, Ji M, Shi B, Chen M, Hou P.
    Thyroid; 2018 Dec; 28(12):1642-1654. PubMed ID: 30226440
    [Abstract] [Full Text] [Related]

  • 3. Aurora A inhibitor (MLN8237) plus vincristine plus rituximab is synthetic lethal and a potential curative therapy in aggressive B-cell non-Hodgkin lymphoma.
    Mahadevan D, Stejskal A, Cooke LS, Manziello A, Morales C, Persky DO, Fisher RI, Miller TP, Qi W.
    Clin Cancer Res; 2012 Apr 15; 18(8):2210-9. PubMed ID: 22374334
    [Abstract] [Full Text] [Related]

  • 4. The aurora kinase A inhibitor MLN8237 enhances cisplatin-induced cell death in esophageal adenocarcinoma cells.
    Sehdev V, Peng D, Soutto M, Washington MK, Revetta F, Ecsedy J, Zaika A, Rau TT, Schneider-Stock R, Belkhiri A, El-Rifai W.
    Mol Cancer Ther; 2012 Mar 15; 11(3):763-74. PubMed ID: 22302096
    [Abstract] [Full Text] [Related]

  • 5. Alisertib added to rituximab and vincristine is synthetic lethal and potentially curative in mice with aggressive DLBCL co-overexpressing MYC and BCL2.
    Mahadevan D, Morales C, Cooke LS, Manziello A, Mount DW, Persky DO, Fisher RI, Miller TP, Qi W.
    PLoS One; 2014 Mar 15; 9(6):e95184. PubMed ID: 24893165
    [Abstract] [Full Text] [Related]

  • 6. Concurrent Inhibition of Neurosphere and Monolayer Cells of Pediatric Glioblastoma by Aurora A Inhibitor MLN8237 Predicted Survival Extension in PDOX Models.
    Kogiso M, Qi L, Braun FK, Injac SG, Zhang L, Du Y, Zhang H, Lin FY, Zhao S, Lindsay H, Su JM, Baxter PA, Adesina AM, Liao D, Qian MG, Berg S, Muscal JA, Li XN.
    Clin Cancer Res; 2018 May 01; 24(9):2159-2170. PubMed ID: 29463553
    [Abstract] [Full Text] [Related]

  • 7. Aurora inhibitor MLN8237 in combination with docetaxel enhances apoptosis and anti-tumor activity in mantle cell lymphoma.
    Qi W, Cooke LS, Liu X, Rimsza L, Roe DJ, Manziolli A, Persky DO, Miller TP, Mahadevan D.
    Biochem Pharmacol; 2011 Apr 01; 81(7):881-90. PubMed ID: 21291867
    [Abstract] [Full Text] [Related]

  • 8. Combination of Eribulin and Aurora A Inhibitor MLN8237 Prevents Metastatic Colonization and Induces Cytotoxic Autophagy in Breast Cancer.
    Kozyreva VK, Kiseleva AA, Ice RJ, Jones BC, Loskutov YV, Matalkah F, Smolkin MB, Marinak K, Livengood RH, Salkeni MA, Wen S, Hazard HW, Layne GP, Walsh CM, Cantrell PS, Kilby GW, Mahavadi S, Shah N, Pugacheva EN.
    Mol Cancer Ther; 2016 Aug 01; 15(8):1809-22. PubMed ID: 27235164
    [Abstract] [Full Text] [Related]

  • 9. Cisplatin-resistant cancer cells are sensitive to Aurora kinase A inhibition by alisertib.
    Wang L, Arras J, Katsha A, Hamdan S, Belkhiri A, Ecsedy J, El-Rifai W.
    Mol Oncol; 2017 Aug 01; 11(8):981-995. PubMed ID: 28417568
    [Abstract] [Full Text] [Related]

  • 10. Targeting Aurora kinase-A downregulates cell proliferation and angiogenesis in neuroblastoma.
    Romain C, Paul P, Kim KW, Lee S, Qiao J, Chung DH.
    J Pediatr Surg; 2014 Jan 01; 49(1):159-65. PubMed ID: 24439602
    [Abstract] [Full Text] [Related]

  • 11. Inhibition of Aurora A enhances radiosensitivity in selected lung cancer cell lines.
    Liu N, Wang YA, Sun Y, Ecsedy J, Sun J, Li X, Wang P.
    Respir Res; 2019 Oct 23; 20(1):230. PubMed ID: 31647033
    [Abstract] [Full Text] [Related]

  • 12. A novel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myeloma.
    Görgün G, Calabrese E, Hideshima T, Ecsedy J, Perrone G, Mani M, Ikeda H, Bianchi G, Hu Y, Cirstea D, Santo L, Tai YT, Nahar S, Zheng M, Bandi M, Carrasco RD, Raje N, Munshi N, Richardson P, Anderson KC.
    Blood; 2010 Jun 24; 115(25):5202-13. PubMed ID: 20382844
    [Abstract] [Full Text] [Related]

  • 13. Antitumor activity of the aurora a selective kinase inhibitor, alisertib, against preclinical models of colorectal cancer.
    Pitts TM, Bradshaw-Pierce EL, Bagby SM, Hyatt SL, Selby HM, Spreafico A, Tentler JJ, McPhillips K, Klauck PJ, Capasso A, Diamond JR, Davis SL, Tan AC, Arcaroli JJ, Purkey A, Messersmith WA, Ecsedy JA, Eckhardt SG.
    Oncotarget; 2016 Aug 02; 7(31):50290-50301. PubMed ID: 27385211
    [Abstract] [Full Text] [Related]

  • 14. Expression profile‑driven discovery of AURKA as a treatment target for liposarcoma.
    Yen CC, Chen SC, Hung GY, Wu PK, Chua WY, Lin YC, Yen CH, Chen YC, Wang JY, Yang MH, Chao Y, Chang MC, Chen WM.
    Int J Oncol; 2019 Oct 02; 55(4):938-948. PubMed ID: 31485600
    [Abstract] [Full Text] [Related]

  • 15. The investigational Aurora kinase A inhibitor MLN8237 induces defects in cell viability and cell-cycle progression in malignant bladder cancer cells in vitro and in vivo.
    Zhou N, Singh K, Mir MC, Parker Y, Lindner D, Dreicer R, Ecsedy JA, Zhang Z, Teh BT, Almasan A, Hansel DE.
    Clin Cancer Res; 2013 Apr 01; 19(7):1717-28. PubMed ID: 23403633
    [Abstract] [Full Text] [Related]

  • 16. MLN8237 ( alisertib ) and its role in peripheral T-cell lymphoma.
    Alrifai D, Pettengell R.
    Expert Opin Investig Drugs; 2014 Dec 01; 23(12):1731-6. PubMed ID: 25323772
    [Abstract] [Full Text] [Related]

  • 17. Initial testing of the aurora kinase A inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP).
    Maris JM, Morton CL, Gorlick R, Kolb EA, Lock R, Carol H, Keir ST, Reynolds CP, Kang MH, Wu J, Smith MA, Houghton PJ.
    Pediatr Blood Cancer; 2010 Jul 15; 55(1):26-34. PubMed ID: 20108338
    [Abstract] [Full Text] [Related]

  • 18. A MYC-aurora kinase A protein complex represents an actionable drug target in p53-altered liver cancer.
    Dauch D, Rudalska R, Cossa G, Nault JC, Kang TW, Wuestefeld T, Hohmeyer A, Imbeaud S, Yevsa T, Hoenicke L, Pantsar T, Bozko P, Malek NP, Longerich T, Laufer S, Poso A, Zucman-Rossi J, Eilers M, Zender L.
    Nat Med; 2016 Jul 15; 22(7):744-53. PubMed ID: 27213815
    [Abstract] [Full Text] [Related]

  • 19. Dual BRD4 and AURKA Inhibition Is Synergistic against MYCN-Amplified and Nonamplified Neuroblastoma.
    Felgenhauer J, Tomino L, Selich-Anderson J, Bopp E, Shah N.
    Neoplasia; 2018 Oct 15; 20(10):965-974. PubMed ID: 30153557
    [Abstract] [Full Text] [Related]

  • 20. The BET bromodomain inhibitor CPI203 overcomes resistance to ABT-199 (venetoclax) by downregulation of BFL-1/A1 in in vitro and in vivo models of MYC+/BCL2+ double hit lymphoma.
    Esteve-Arenys A, Valero JG, Chamorro-Jorganes A, Gonzalez D, Rodriguez V, Dlouhy I, Salaverria I, Campo E, Colomer D, Martinez A, Rymkiewicz G, Pérez-Galán P, Lopez-Guillermo A, Roué G.
    Oncogene; 2018 Apr 15; 37(14):1830-1844. PubMed ID: 29353886
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.